Graham Capital Management’s Cabaletta Bio CABA Stock Holding History

Graham Capital Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Sell	81,279 -20,409	-20%	-$67.1K	﹤0.01%	961
2026 Q1	$274K	Sell	101,688 -49,763	-33%	-$138K	0.01%	850
2025 Q4	$332K	Buy	+151,451	New	+$375K	0.01%	817
2024 Q4	–	Sell	-23,571	Closed	-$111K	–	1246
2024 Q3	$111K	Buy	23,571 +5,605	+31%	+$32.4K	﹤0.01%	997
2024 Q2	$134K	Sell	17,966 -13,208	-42%	-$162K	﹤0.01%	912
2024 Q1	$532K	Buy	+31,174	New	+$669K	0.01%	611

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Graham Capital Management's CABA Position: Q2 2026 in Review

Graham Capital Management reduced its Cabaletta Bio (CABA) stake by 20% in Q2 2026, selling an estimated $67.1K and leaving 81,279 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Graham Capital Management first reported a position in CABA in Q1 2024 and has held it in 6 quarters since. The position peaked at $532K in Q1 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Graham Capital Management held 81,279 shares of Cabaletta Bio worth $253K as of Q2 2026.
Graham Capital Management sold 20,409 Cabaletta Bio shares in Q2 2026, an estimated $67.1K.
Cabaletta Bio made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #961 holding.
Graham Capital Management first reported a position in Cabaletta Bio in Q1 2024 and has held it in 6 quarters since.
Graham Capital Management's Cabaletta Bio position peaked at $532K in Q1 2024.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.